US Trade Commission Judge Recommends Seven-Year Ban on Hong Kong Firm Over Liver Drug Marketing Dispute

In a recent development, the U.S. International Trade Commission’s chief judge has advised the agency to enforce a significant restriction on a Hong Kong-based drug developer. The recommendation involves a seven-year prohibition against the company marketing unapproved treatments for a specific liver disease, which could represent a strategic win for a competing company that is also pursuing treatment solutions for the same medical condition. For further details, the complete overview of the judicial advice is available in a report by Law360.